anondita medicare has secured a purchase order worth ₹7,18,36,178.31 from the Central Medical Services Society (CMSS), Ministry of Health and Family Welfare. The order, dated April 28, 2026, is for the supply of condoms (FS-NACO) and was disclosed to the National Stock Exchange of India Limited on May 25, 2026. The company confirmed that the disclosure was made after obtaining necessary clarifications from CMSS regarding the final accepted quantity and the applicability of the Rate Contract.

Order Details

The purchase order (PO No: 10282600131/PDI/Domestic Fund-DF) stipulates a delivery schedule divided into two tranches. The first tranche requires 50% of the total delivery to be completed within 90 days from the date of the purchase order. The remaining 50% must be delivered within 91 to 180 days from the purchase order date.

Financial and Contractual Terms

The total value of the order is ₹7,18,36,178.31. The contract requires the company to deposit a performance security equivalent to 3% of the total order value via NEFT, RTGS, Demand Draft, Banker's Cheque, Fixed Deposit Receipt, or Bank Guarantee. This security must be submitted within 15 days of receiving the order letter, or the amount will be deducted from payments due.

Payment terms are structured based on the type of supplies. For items requiring sterility tests, payments will be made within 75 days of supply. For other items, the payment timeline is 60 days. Part payments will only be considered after 50% of the ordered items in an individual tranche have been supplied, provided standard quality testing reports are received from CMSS laboratories.

The company confirmed that the order has been awarded by a domestic entity and that there is no interest from the promoter, promoter group, or group companies in the entity awarding the order. The transaction does not fall under related party transactions.

Anondita Medicare has issued a second corrigendum to the notice of its 01/2026-27 Extraordinary General Meeting (EGM), scheduled for May 28, 2026. The revision addresses a change in the valuation working under Regulation 164 of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, leading to an adjustment in the applicable 90 trading day price-band period. The company informed the National Stock Exchange of India (NSE) that a revised valuation report has been obtained from the Registered Valuer.

The Board has fixed the issue price at ₹1,038 per warrant, which remains above the minimum price determined by the Registered Valuer. The valuation parameters include book value and comparable trading multiples. The corrigendum updates Point No. 6 of the explanatory statement regarding the basis of price determination and Point No. 23 concerning the Practicing Company Secretary’s Certificate.

Terms of the Preferential Issue

The EGM seeks shareholder approval to allot up to 2,85,000 convertible warrants to promoter Anupam Ghosh. Each warrant is convertible into one fully paid-up equity share with a face value of ₹10. The total issue size aggregates to ₹29,58,30,000.

Payment for the warrants is structured in two tranches. A minimum of 25% of the warrant issue price, amounting to ₹7,39,57,500, must be paid at the time of subscription and allotment. The remaining 75%, totaling ₹22,18,72,500, is payable upon the exercise of the right to convert the warrants into equity shares within 18 months from the date of allotment.

Valuation and Certification

The revised valuation was performed by Mr. Ankush Garg, a Registered Valuer (Registration No. IBBI/RV/02/2018/10010). The revised certificate confirming the minimum price is available for inspection at the Registered Office and on the company’s website. Additionally, the certificate from Mr. Mohit Singhal, Practicing Company Secretary (FCS 11143 | CP 15995), certifying compliance with SEBI ICDR Regulations, has been updated and made available to members.